Oxford Brain Diagnostics (OBD) is set to launch its innovative Cortical Disarray Measurement (CDM) software for early dementia diagnosis in the UK and US. This follows successful regulatory approvals from the FDA and UKCA, which allow the technology to be used in major healthcare markets. The CDM software utilizes standard MRI scans for accurate neurodegeneration measurement, enhancing early Alzheimer's detection. Co-founded in 2019 by Dr. Steven Chance and Professor Mark Jenkinson, OBD aims to revolutionize brain health assessments and tackle the increasing public health challenge posed by neurodegenerative diseases.
Neurodegenerative diseases represent a growing public health challenge, said Dr Steven Chance, CEO and co-founder of OBD. The support from BGF... has been instrumental in taking CDM from the lab to the clinic.
The rollout of CDM follows successful FDA 510(k) clearance and UKCA self-certification, providing the regulatory green light for entry into significant healthcare markets.
#dementia-diagnosis #neurodegenerative-diseases #healthcare-innovation #mri-technology #regulatory-approvals
Collection
[
|
...
]